Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy.
Yehoda M MarteiMohan NarasimhamurthyDipho I SetlhakoGezahen AyaneTlotlo B RalefalaSebathu ChiyapoRobert GrossLawrence N ShulmanSurbhi GroverAngela M DeMichelePublished in: JCO global oncology (2022)
Patients who are HIV-positive and have breast cancer in Botswana have lower pCR rates and also receive lower dose intensity therapy, which may contribute to worse OS. Patients who are HIV-positive on ZDV-containing regimens received even lower dose intensity of NACT. Administering optimal dose intensity in patients who are HIV-positive remains a challenge, and targeted interventions that address modifiable risk factors are needed to improve therapy delivery and outcomes.
Keyphrases
- hiv positive
- men who have sex with men
- antiretroviral therapy
- end stage renal disease
- south africa
- neoadjuvant chemotherapy
- ejection fraction
- newly diagnosed
- risk factors
- human immunodeficiency virus
- peritoneal dialysis
- hiv testing
- prognostic factors
- high intensity
- hiv infected
- squamous cell carcinoma
- physical activity
- radiation therapy
- hepatitis c virus
- drug delivery
- early stage
- adipose tissue
- skeletal muscle
- insulin resistance
- patient reported
- sentinel lymph node